Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer

Kazuhiro Matsumoto, Eiji Kikuchi, Hiroshi Shirakawa, Nozomi Hayakawa, Nobuyuki Tanaka, Akiharu Ninomiya, Akira Miyajima, So Nakamura, Mototsugu Oya

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OBJECTIVE • To investigate the risk of subsequent tumour recurrence and stage progression in bacillus Calmette-Guérin (BCG)-relapsing non-muscle-invasive bladder cancer, defined as recurrence after achieving a disease-free status for 6 months. PATIENTS AND METHODS • A total of 183 patients with BCGrelapsing tumours were treated with conservative therapy between 1985 and 2008 at our three institutions. • We analysed the association between their clinicopathological parameters and subsequent tumour recurrence or stage progression. RESULTS • Additional induction courses of BCG or anticancer drug (mitomycin C or epirubicin) instillations were performed in 119 patients and 24 patients, respectively. The remaining 40 patients did not undergo any adjuvant therapy. • Multivariate analysis showed that a relapsing tumour with a pathologically high risk (defined as tumours with G3 and/or pT1 and/or concomitant carcinoma in situ ) was a significant risk factor for subsequent tumour recurrence ( P = 0.002; hazard ratio [ HR ] 2.15). Additional BCG instillation significantly decreased the subsequent tumour recurrence rate ( P < 0.001; HR 0.41). • Multivariate analysis also showed that a relapsing tumour with a pathologically high risk was also significantly associated with stage progression ( P < 0.001; HR 8.05). CONCLUSIONS • An additional course of BCG instillation might be effective in patients with BCG-relapsing tumours with pathologically intermediate risk. • Nevertheless, some patients with high-risk pathological features developed subsequent stage progression. Such patients should be followed up closely and counselled on the need for aggressive therapeutic options, such as radical cystectomy.

Original languageEnglish
JournalBJU International
Volume110
Issue number11 B
DOIs
Publication statusPublished - 2012 Dec

Fingerprint

Urinary Bladder Neoplasms
Recurrence
Bacillus
Neoplasms
Multivariate Analysis
Epirubicin
Cystectomy
Carcinoma in Situ
Mitomycin
Therapeutics
Pharmaceutical Preparations

Keywords

  • Bacille Calmette-Guérin
  • BCG failure
  • BCG relapsing
  • Non-muscle-invasive bladder cancer
  • Stage progression
  • Tumour recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer. / Matsumoto, Kazuhiro; Kikuchi, Eiji; Shirakawa, Hiroshi; Hayakawa, Nozomi; Tanaka, Nobuyuki; Ninomiya, Akiharu; Miyajima, Akira; Nakamura, So; Oya, Mototsugu.

In: BJU International, Vol. 110, No. 11 B, 12.2012.

Research output: Contribution to journalArticle

Matsumoto, Kazuhiro ; Kikuchi, Eiji ; Shirakawa, Hiroshi ; Hayakawa, Nozomi ; Tanaka, Nobuyuki ; Ninomiya, Akiharu ; Miyajima, Akira ; Nakamura, So ; Oya, Mototsugu. / Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer. In: BJU International. 2012 ; Vol. 110, No. 11 B.
@article{17813c211e1343659b12b7f2487d49ec,
title = "Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Gu{\'e}rin relapsing non-muscle-invasive bladder cancer",
abstract = "OBJECTIVE • To investigate the risk of subsequent tumour recurrence and stage progression in bacillus Calmette-Gu{\'e}rin (BCG)-relapsing non-muscle-invasive bladder cancer, defined as recurrence after achieving a disease-free status for 6 months. PATIENTS AND METHODS • A total of 183 patients with BCGrelapsing tumours were treated with conservative therapy between 1985 and 2008 at our three institutions. • We analysed the association between their clinicopathological parameters and subsequent tumour recurrence or stage progression. RESULTS • Additional induction courses of BCG or anticancer drug (mitomycin C or epirubicin) instillations were performed in 119 patients and 24 patients, respectively. The remaining 40 patients did not undergo any adjuvant therapy. • Multivariate analysis showed that a relapsing tumour with a pathologically high risk (defined as tumours with G3 and/or pT1 and/or concomitant carcinoma in situ ) was a significant risk factor for subsequent tumour recurrence ( P = 0.002; hazard ratio [ HR ] 2.15). Additional BCG instillation significantly decreased the subsequent tumour recurrence rate ( P < 0.001; HR 0.41). • Multivariate analysis also showed that a relapsing tumour with a pathologically high risk was also significantly associated with stage progression ( P < 0.001; HR 8.05). CONCLUSIONS • An additional course of BCG instillation might be effective in patients with BCG-relapsing tumours with pathologically intermediate risk. • Nevertheless, some patients with high-risk pathological features developed subsequent stage progression. Such patients should be followed up closely and counselled on the need for aggressive therapeutic options, such as radical cystectomy.",
keywords = "Bacille Calmette-Gu{\'e}rin, BCG failure, BCG relapsing, Non-muscle-invasive bladder cancer, Stage progression, Tumour recurrence",
author = "Kazuhiro Matsumoto and Eiji Kikuchi and Hiroshi Shirakawa and Nozomi Hayakawa and Nobuyuki Tanaka and Akiharu Ninomiya and Akira Miyajima and So Nakamura and Mototsugu Oya",
year = "2012",
month = "12",
doi = "10.1111/j.1464-410X.2012.11194.x",
language = "English",
volume = "110",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "11 B",

}

TY - JOUR

T1 - Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer

AU - Matsumoto, Kazuhiro

AU - Kikuchi, Eiji

AU - Shirakawa, Hiroshi

AU - Hayakawa, Nozomi

AU - Tanaka, Nobuyuki

AU - Ninomiya, Akiharu

AU - Miyajima, Akira

AU - Nakamura, So

AU - Oya, Mototsugu

PY - 2012/12

Y1 - 2012/12

N2 - OBJECTIVE • To investigate the risk of subsequent tumour recurrence and stage progression in bacillus Calmette-Guérin (BCG)-relapsing non-muscle-invasive bladder cancer, defined as recurrence after achieving a disease-free status for 6 months. PATIENTS AND METHODS • A total of 183 patients with BCGrelapsing tumours were treated with conservative therapy between 1985 and 2008 at our three institutions. • We analysed the association between their clinicopathological parameters and subsequent tumour recurrence or stage progression. RESULTS • Additional induction courses of BCG or anticancer drug (mitomycin C or epirubicin) instillations were performed in 119 patients and 24 patients, respectively. The remaining 40 patients did not undergo any adjuvant therapy. • Multivariate analysis showed that a relapsing tumour with a pathologically high risk (defined as tumours with G3 and/or pT1 and/or concomitant carcinoma in situ ) was a significant risk factor for subsequent tumour recurrence ( P = 0.002; hazard ratio [ HR ] 2.15). Additional BCG instillation significantly decreased the subsequent tumour recurrence rate ( P < 0.001; HR 0.41). • Multivariate analysis also showed that a relapsing tumour with a pathologically high risk was also significantly associated with stage progression ( P < 0.001; HR 8.05). CONCLUSIONS • An additional course of BCG instillation might be effective in patients with BCG-relapsing tumours with pathologically intermediate risk. • Nevertheless, some patients with high-risk pathological features developed subsequent stage progression. Such patients should be followed up closely and counselled on the need for aggressive therapeutic options, such as radical cystectomy.

AB - OBJECTIVE • To investigate the risk of subsequent tumour recurrence and stage progression in bacillus Calmette-Guérin (BCG)-relapsing non-muscle-invasive bladder cancer, defined as recurrence after achieving a disease-free status for 6 months. PATIENTS AND METHODS • A total of 183 patients with BCGrelapsing tumours were treated with conservative therapy between 1985 and 2008 at our three institutions. • We analysed the association between their clinicopathological parameters and subsequent tumour recurrence or stage progression. RESULTS • Additional induction courses of BCG or anticancer drug (mitomycin C or epirubicin) instillations were performed in 119 patients and 24 patients, respectively. The remaining 40 patients did not undergo any adjuvant therapy. • Multivariate analysis showed that a relapsing tumour with a pathologically high risk (defined as tumours with G3 and/or pT1 and/or concomitant carcinoma in situ ) was a significant risk factor for subsequent tumour recurrence ( P = 0.002; hazard ratio [ HR ] 2.15). Additional BCG instillation significantly decreased the subsequent tumour recurrence rate ( P < 0.001; HR 0.41). • Multivariate analysis also showed that a relapsing tumour with a pathologically high risk was also significantly associated with stage progression ( P < 0.001; HR 8.05). CONCLUSIONS • An additional course of BCG instillation might be effective in patients with BCG-relapsing tumours with pathologically intermediate risk. • Nevertheless, some patients with high-risk pathological features developed subsequent stage progression. Such patients should be followed up closely and counselled on the need for aggressive therapeutic options, such as radical cystectomy.

KW - Bacille Calmette-Guérin

KW - BCG failure

KW - BCG relapsing

KW - Non-muscle-invasive bladder cancer

KW - Stage progression

KW - Tumour recurrence

UR - http://www.scopus.com/inward/record.url?scp=84876421194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876421194&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2012.11194.x

DO - 10.1111/j.1464-410X.2012.11194.x

M3 - Article

VL - 110

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 11 B

ER -